S. Huang et al., ROLE OF A2A EXTRACELLULAR ADENOSINE RECEPTOR-MEDIATED SIGNALING IN ADENOSINE-MEDIATED INHIBITION OF T-CELL ACTIVATION AND EXPANSION, Blood, 90(4), 1997, pp. 1600-1610
Accumulation of adenosine and of deoxyadenosine in the absence of aden
osine deaminase activity (ADA) activity results in lymphocyte depletio
n and in severe combined immunodeficiency (ADA SCID), which is current
ly explained by direct cell death-causing effects of intracellular pro
ducts of adenosine metabolism, We explored the alternative mechanisms
of peripheral T-cell depletion as due to inhibition of T-cell expansio
n by extracellular adenosine mediated signaling through purinergic rec
eptors, The strong inhibition of the T-cell receptor (TCR)-triggered p
roliferation and of upregulation of interleukin-2 receptor alpha chain
(CD25) molecules, but not the direct lymphotoxicity, were observed at
low concentrations of extracellular adenosine. These effects of extra
cellular adenosine (Ado) are likely to be mediated by A2a receptor-med
iated signaling rather than by intracellular toxicity of adenosine cat
abolites, because (1) poorly metabolized adenosine analogs cause the a
ccumulation of cAMP and strong inhibition of TCR-triggered CD25 upregu
lation; (2) the A2a, but not the A? or A3, receptors are the major exp
ressed and functionally coupled adenosine receptors in mouse periphera
l T and B lymphocytes, and the adenosine-induced cAMP accumulation in
lymphocytes correlates with the expression of A2a receptors; (3) the s
pecific agonist of A2a receptor, CGS21680, induces increases in [cAMP]
i in lymphocytes, whereas the specific antagonist of A2a receptor, CSC
, inhibits the effects of Ado and CGS21680; and (4) the increases in [
cAMP]i mimic the adenosine-induced inhibition of TCR-triggered CD25 up
regulation and splenocyte proliferation. These studies suggest the pos
sible Pole of adenosine receptors in the regulation of lymphocyte expa
nsion and point to the downregulation of A2a purinergic receptors on T
cells as a potentially attractive pharmacologic target. (C) 1997 by T
he American Society of Hematology.